stars 1 stars 2 stars 3

Globally, 10 million new cases every year and 4000 people die every day due to Tuberculosis (TB). TB is curable if detected at early stages and treated with correct antibiotics. If not, the TB bacteria develops resistance and becomes a challenge for diagnosis and treatment. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of drug-resistant TB in the community. EMPE Diagnostics AB, Sweden is dedicated to confronting the global burden of tuberculosis (TB) through advanced molecular diagnostics engineered specifically to address the complexities of molecular drug resistance testing. By leveraging the power of our molecular platform, we are on the cusp of launching the CircuLOK product range for detecting of multidrug-resistant (MDR) and pre-extensively drug-resistant (pre-XDR) tuberculosis, empowering labs with limited resources to reliably detect resistance to rifampicin, isoniazid and fluoroquinolones.

EMPE Diagnostics Questions

The EMPE Diagnostics annual revenue was $6 million in 2026.

Poonam Singh is the VP Innovation and R and D of EMPE Diagnostics.

19 people are employed at EMPE Diagnostics.

EMPE Diagnostics is based in Solna, Stockholm.

The NAICS codes for EMPE Diagnostics are [541, 54171, 541713, 5417, 54].

The SIC codes for EMPE Diagnostics are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users